BLINATUMOMAB and INFECTION

Overview

INFECTION is the #13 most commonly reported adverse reaction for BLINATUMOMAB, manufactured by Amgen, Inc. There are 246 FDA adverse event reports linking BLINATUMOMAB to INFECTION. This represents approximately 1.5% of all 16,815 adverse event reports for this drug.

Patients taking BLINATUMOMAB who experience infection should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

INFECTION is a less commonly reported adverse event for BLINATUMOMAB, but still significant enough to appear in the safety profile.

Other Side Effects of BLINATUMOMAB

In addition to infection, the following adverse reactions have been reported for BLINATUMOMAB:

• PYREXIA — 1,108 reports
• ACUTE LYMPHOCYTIC LEUKAEMIA RECURRENT — 1,041 reports
• CYTOKINE RELEASE SYNDROME — 1,014 reports
• OFF LABEL USE — 689 reports
• DEATH — 627 reports
• NEUROTOXICITY — 560 reports
• DRUG INEFFECTIVE — 408 reports
• HEADACHE — 352 reports
• FEBRILE NEUTROPENIA — 298 reports
• NEUTROPENIA — 298 reports

Other Drugs Associated with INFECTION

The following drugs have also been linked to infection in FDA adverse event reports:

Does BLINATUMOMAB cause INFECTION?

INFECTION has been reported as an adverse event in 246 FDA reports for BLINATUMOMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is INFECTION with BLINATUMOMAB?

INFECTION accounts for approximately 1.5% of all adverse event reports for BLINATUMOMAB, making it a notable side effect.

What should I do if I experience INFECTION while taking BLINATUMOMAB?

If you experience infection while taking BLINATUMOMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages